Studies using transgenic animals have shown that increased truncated SREBP-2, without a regulatory domain, can lead to alteration of insulin secretion, lower pancreatic β-cell (PBC) count, diabetes, reduced fat reserves, lower weight, increased total cholesterol in blood and tissues, and non-alcoholic hepatic steatosis [6]. The gene discussed is SREBF2; the disease is fatty liver disease.